Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Executive Summary
Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance
You may also be interested in...
Are FDA And CMS Growing Apart? AEI’s Gottlieb Thinks So
While many pharmaceutical industry observers like to talk about the new ways in which FDA and CMS are working together and sharing information, Scott Gottlieb is offering a contrarian view on relations between the two agencies
The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?
The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands
Are FDA And CMS Growing Apart? AEI’s Gottlieb Thinks So
While many pharmaceutical industry observers like to talk about the new ways in which FDA and CMS are working together and sharing information, Scott Gottlieb is offering a contrarian view on relations between the two agencies